Focus Partners Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Focus Partners Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Sell	44,652 -10,111	-18%	-$554K	﹤0.01%	1248
2026 Q1	$3.09M	Buy	54,763 +14,985	+38%	+$874K	﹤0.01%	1120
2025 Q4	$2.36M	Buy	39,778 +12,300	+45%	+$670K	﹤0.01%	1255
2025 Q3	$1.49M	Buy	27,478 +8,898	+48%	+$509K	﹤0.01%	1127
2025 Q2	$1.02M	Buy	18,580 +6,763	+57%	+$398K	﹤0.01%	1133
2025 Q1	$835K	Buy	11,817 +4,518	+62%	+$304K	﹤0.01%	1128
2024 Q4	$480K	Buy	+7,299	New	+$489K	﹤0.01%	1353

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Focus Partners Wealth's BMRN Position: Q2 2026 in Review

Focus Partners Wealth reduced its BioMarin Pharmaceuticals (BMRN) stake by 18% in Q2 2026, selling an estimated $554K and leaving 44,652 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

Focus Partners Wealth first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.09M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Focus Partners Wealth held 44,652 shares of BioMarin Pharmaceuticals worth $2.56M as of Q2 2026.
Focus Partners Wealth sold 10,111 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $554K.
BioMarin Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1248 holding.
Focus Partners Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Focus Partners Wealth's BioMarin Pharmaceuticals position peaked at $3.09M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.